Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Total Liabilities (2016 - 2025)

VYNE Therapeutics' Total Liabilities history spans 10 years, with the latest figure at $2.4 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 83.84% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $2.4 million, down 83.84%, while the annual FY2025 figure was $2.4 million, 83.84% down from the prior year.
  • Total Liabilities reached $2.4 million in Q4 2025 per VYNE's latest filing, down from $5.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $59.1 million in Q2 2021 to a low of $2.4 million in Q4 2025.
  • Average Total Liabilities over 5 years is $15.2 million, with a median of $9.0 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: plummeted 88.43% in 2022, then soared 65.58% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $18.4 million in 2021, then crashed by 49.24% to $9.3 million in 2022, then dropped by 4.23% to $9.0 million in 2023, then soared by 65.58% to $14.8 million in 2024, then plummeted by 83.84% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Total Liabilities are $2.4 million (Q4 2025), $5.8 million (Q2 2025), and $12.3 million (Q1 2025).